



FIRST INTERNATIONAL SYMPOSIUM ON
PEDIATRIC RENOVASCULAR
HYPERTENSION

September 4, 2019

Registration open for inaugural symposium on pediatric renovascular hypertension

Ann Arbor — A new symposium organized by University of Michigan Medical School faculty aims to improve outcomes for patients with pediatric renovascular hypertension (PRVH), a rare but potentially life-threatening disorder.

The First International Symposium on Pediatric Renovascular Hypertension will take place **November 11-12** in Ann Arbor, Michigan, on the U-M medical campus. The target audience includes multidisciplinary care providers that manage (and refer) infants and children with renovascular hypertension, not limited to pediatric nephrologists, cardiologists, radiologists and surgeons.

Admission is free and continuing medical education credits are expected to be available to physicians. For the full program agenda, registration link and travel information, visit UMichPediRVHSymposium.org.

Best practices for detection & lifesaving treatment

Pediatric renovascular hypertension secondary to renal artery occlusive lesions and abdominal aortic coarctation risks significant morbidity and mortality. The timely detection and treatment of such is critical to preventing ischemic nephropathy, chronic kidney disease, cardiopulmonary complications and stroke.

The pathophysiology remains poorly defined; additionally, the low frequency of this disease limits existing data to institutional series and anecdotal case reports. As such, the optimal management of these children remains ill-defined.

Moreover, the introduction and expansion of novel open surgical and endovascular techniques for the revascularization of aortic and renal artery lesions for these children has dramatically changed the landscape of patient care in the last decade.

As multidisciplinary high volume referral centers of excellence are few, across the globe, patients and families may be challenged to balance vastly differing sets of recommendations.

Research is urgently needed to advance our understanding of this disease and define best practices in the care of these special children as it relates to medical therapy, patient selection for revascularization and technical approaches for such that consider specific patient and anatomic phenotype.

International expertise

A geographically diverse, multi-disciplinary planning committee has drawn on the expertise of physicians from The Hospital for Sick Children (Toronto), Great Ormond Street Hospital (London), Boston Children's Hospital, Children's Hospital of Philadelphia and the University of Michigan. **The First International Symposium on Pediatric Renovascular Hypertension** will highlight an international array of distinguished physicians and

researchers, highlighting the best practices in patient care, recent discovery and ongoing research. Additionally, urgent research needs will be prioritized for further study.

The symposium will feature a keynote address delivered by **Harry Dietz III, MD**, of the Johns Hopkins University School of Medicine. Dr. Dietz, as the Victor A. McKusick Professor of Genetics, also serves as the director of the William S. Smilow Center for Marfan Syndrome Research and will speak to his own personal experience with gene discovery and translational efforts as the world's leading authority on Marfan Syndrome and related disorders.

The program includes moderated scientific and clinical sessions, devoted to general information about the condition, diagnostic imaging, medical management, revascularization options and current research, in addition to expert panels.

The symposium is sponsored by the University of Michigan's **Taubman Institute**, which was founded in 2007 by the late entrepreneur and philanthropist A. Alfred Taubman, to support the work of physician researchers with financial grants, the Taubman Prize and other programs. Learn more at TaubmanInstitute.org.

"Helping passionate clinician-scientists launch projects that generate better outcomes for patients and their families is the fundamental mission of the Taubman Institute," said the institute's director, Charles F. Burant, MD, PhD. "We are delighted to sponsor this inaugural symposium in hopes it will lead to more timely, personalized treatment for every child with the condition."

Contact: Melissa Preddy
mpreddy@med.umich.edu
(734) 218-2043

Follow on Twitter @[PediRVH2019](https://twitter.com/PediRVH2019) for news and updates.

